IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy |
|
|
| Active, not recruiting | 2 | 46 | Europe, RoW | Imetelstat sodium, GRN163L | GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 02/25 | 06/26 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
